Walleye Capital LLC Astria Therapeutics, Inc. Transaction History
Walleye Capital LLC
- $24 Billion
- Q3 2025
A detailed history of Walleye Capital LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 3,439 shares of ATXS stock, worth $43,228. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,439
Previous 102,349
96.64%
Holding current value
$43,228
Previous $548,000
95.62%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ATXS
# of Institutions
121Shares Held
50.8MCall Options Held
48.8KPut Options Held
55.8K-
Perceptive Advisors LLC New York, NY6.49MShares$81.5 Million0.1% of portfolio
-
Vestal Point Capital, LP New York, NY4.96MShares$62.3 Million1.63% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$51.6 Million5.98% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$44.7 Million5.59% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$44.2 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $191M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...